ESC 365 - Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban

ESC Professional Premium Access

Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban

Session: Clinical decision-making about oral anticoagulant therapy in atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Mr M. Yeo (Seoul, KR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Muhan Yeo

Seoul National University College of Medicine, Seoul (Korea (Republic of))

0 follower

8 more presentations in this session

Switching from warfarin to a DOAC in frail elderly asian patients with atrial fibrillation: a nationwide population-based study

Speaker: Doctor Y. Go (Seoul, KR)

Drug interactions in incident NOACs users and risk of bleeding

Speaker: Doctor M. Amadori (Bologna, IT)

Impact of real-world off-label dose of Apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease

Speaker: Doctor H. Shin (Busan, KR)

Resumption of anticoagulation therapy among Non-Valvular Atrial Fibrillation (NVAF) patients with prior intracranial haemorrhage

Speaker: Doctor W. Sun (Shatin, HK)

Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation

Speaker: Doctor Y. Gue (Liverpool, GB)

Access the full session

Clinical decision-making about oral anticoagulant therapy in atrial fibrillation

Speakers: Mr M. Yeo, Doctor Y. Go, Doctor M. Amadori, Doctor H. Shin, Doctor W. Sun...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources